TNF and Dupuytren Contracture: A trial to evaluate the efficacy of a drug to inhibit tumour necrosis factor is ongoing (Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) trial (ISRCTN27786905 DOI 10.1186/ISRCTN27786905) based on laboratory data showing the key role of this cytokine in the development and maintenance of the phenotype of myofibroblasts [14], the cells responsible for both the excessive matrix deposition and contraction [15].